AVITA Medical, Inc. (RCEL)
10.97
+0.21
(+1.95%)
USD |
NASDAQ |
Sep 03, 16:00
10.95
-0.02
(-0.18%)
After-Hours: 20:00
AVITA Medical Research and Development Expense (TTM) : 20.15M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 20.15M |
| March 31, 2026 | 20.18M |
| December 31, 2025 | 20.84M |
| September 30, 2025 | 20.00M |
| June 30, 2025 | 21.68M |
| March 31, 2025 | 21.45M |
| December 31, 2024 | 20.36M |
| September 30, 2024 | 22.27M |
| June 30, 2024 | 21.24M |
| March 31, 2024 | 21.43M |
| Date | Value |
|---|---|
| December 31, 2023 | 20.82M |
| September 30, 2023 | 17.44M |
| June 30, 2023 | 16.84M |
| March 31, 2023 | 14.82M |
| December 31, 2022 | 13.86M |
| September 30, 2022 | 14.45M |
| June 30, 2022 | 14.76M |
| March 31, 2022 | 15.06M |
| June 30, 2021 | 14.65M |
| March 31, 2021 | 13.01M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Halozyme Therapeutics, Inc. | 102.37M |
| Iovance Biotherapeutics, Inc. | 267.71M |
| Editas Medicine, Inc. | 82.53M |
| Arcus Biosciences, Inc. | 497.00M |
| Recursion Pharmaceuticals, Inc. | 344.11M |